Health-related quality of life of patients with prostate cancer initiating GnRH agonist therapy: the PRISME study
| Autor: | François Rozet, Christophe Hennequin, Pierre Mongiat-Artus, Nathalie Pello-Leprince-Ringuet, Anne-Sophie Grandoulier, Morgan Roupret |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | The Aging Male, Vol 27, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 13685538 1473-0790 1368-5538 |
| DOI: | 10.1080/13685538.2024.2406547 |
| Popis: | Objectives To compare the evolution of health-related quality of life (HRQoL) over 6 months of GnRH agonist (GnRHa) therapy among age groups for patients with prostate cancer (PCa).Patients and methods PRISME (NCT03516110) was a non-interventional, prospective study conducted in France in patients aged ≥60 years with PCa initiating GnRHa therapy within routine care. HRQoL was evaluated at baseline and after 6 months using the EORTC quality of life in ELDerly cancer patients 14 items (QLQ-ELD14) questionnaire. Cognitive status was assessed using the Mini Mental State Examination (MMSE). Analyses of covariance compared the evolution of the change from baseline of the QLQ-ELD14 scores among age groups.Results 814 patients were enrolled (245, 60–70 years; 314, 70–75 years; 252, ≥75 years). Slight or no changes were observed in each QLQ-ELD14 dimension between baseline and 6 months, overall and by age. In the primary effectiveness analysis, there was no difference among age groups in the change from baseline in QLQ-ELD14 scores. Baseline cognitive status was lower in the oldest age group, but there were no changes in all age groups. As expected, sexual function declined in all age groups.Conclusion GnRHa therapy influence on HRQoL, cognition and sexuality appeared independent of age. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|